stockrowAbbVie Inc. (ABBV) vs Gilead Sciences, Inc. (GILD)
- AbbVie Inc. ABBV 290.33 +0.73%
- Gilead Sciences, Inc. GILD 167.80 +0.14%
AbbVie Inc. and Gilead Sciences, Inc. are both Drug Manufacturers General companies. AbbVie Inc. is the larger, with a market value of $509.5B against $207.8B — 2.5× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; AbbVie Inc. trades at 49.7×. AbbVie Inc. grew revenue faster over the last twelve months: 10.7% against 6.54%. AbbVie Inc. has the higher net margin (15.6% vs −12.5%) and the higher return on invested capital (20.2% vs −4.51%). Both pay a dividend; AbbVie Inc. yields more (2.40% vs 1.94%). Across the 21 metrics below, Gilead Sciences, Inc. leads on 11 and AbbVie Inc. on 10.
Valuation
Profitability
| Metric | ABBV | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 73.72% | 79.93% | 73.01% |
| Operating margin | 32.16% | (7.63%) | 18.34% |
| Net margin | 15.61% | (12.47%) | 7.31% |
| Free cash flow margin | 28.59% | 44.47% | 18.52% |
| Return on equity | (288.69%) | (22.45%) | 5.80% |
| Return on assets | 7.32% | (7.03%) | 2.28% |
| Return on invested capital | 20.23% | (4.51%) | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack